RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response

Hennings, Johannes M.; Uhr, Manfred; Klengel, Torsten; Weber, Peter; Pütz, Benno; Touma, Chadi; Ising, Marcus; Holsboer, Florian; Lucae, Susanne

doi:10.1055/s-0035-1557957

Cited by 1 publication

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A replication study in a separate sample of 142 depressed inpatients supported a significant association with treatment response with lower expression of retinoidrelated orphan receptor alpha (RORa), germinal center expressed transcript 2 (GCET2), and chitinase 3-like protein 2 (CHI3L2). Lower expression of RORa, a clock gene involved in generating circadian rhythms and steroid hormone receptors, was also found to be associated with higher plasma corticosterone levels in stress reactive mice in this study [50]. While significant, the association of RORa with treatment response was Bslight,^and in the absence of non-depressed controls, it is not clear that the reported association was with a response of depression rather than a nonspecific element of the stress response.…”

Section: Gene Network Studiescontrasting

confidence: 43%

“…A German genome-wide transcriptomics study of 24 moderately depressed inpatients, openly treated for 5 weeks with their physicians' choice of antidepressant, compared 12 remitters (equivalent to 17-item Hamilton Rating Scale for Depression [HRSD] score <7) with 12 age-and severity-matched nonresponders (<25 % improvement) [50]. The authors identified 127 gene transcripts that had a significant association with remission.…”

Section: Gene Network Studiesmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Pharmacogenomics to Guide Treatment in Mood and Anxiety Disorders

Dubovsky

2015

Curr Behav Neurosci Rep

View full text Add to dashboard Cite

Interest has grown in genetic testing to personalize treatment approaches in psychiatry, especially mood disorders and to a lesser extent anxiety. However, numerous studies of genetic variants of metabolizing enzymes, along with fewer studies of single nucleotide polymorphisms of drug transporter proteins, receptors, and other putative drug targets such as neurotransmitter reuptake pumps and receptors, have reported contradictory findings that have not translated into practical, costeffective treatment recommendations. In this article, we review basic principles of genetic testing and highlight selected elements of genetic testing in cancer. We then critically review the current status of genetic research in pharmacokinetics and pharmacodynamics, as well as the few clinical trials that have been performed. After discussing the limited clinical applications of current research, we make recommendations for developing more clinically useful studies of cost-effective approaches to genetic testing in the treatment of mood and anxiety disorders.

show abstract

Section: Gene Network Studiescontrasting

confidence: 43%

Section: Gene Network Studiesmentioning

confidence: 99%